This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a prospective, randomised, double-blind, clinical trial that was carried out at 40 outpatient cardiology centres and psychiatry clinics in the USA, Europe, Canada and Australia. Treatment was provided for 24 weeks. Details on randomisation and follow-up were not reported. The length of follow-up might have been 6 months. Researchers blinded to treatment allocation assessed the outcomes. Events occurring in the 30 days following the study duration were also recorded because they might have been treatment-related.
Analysis of effectiveness
The clinical outcomes appear to have been assessed among all treated patients (intention to treat, ITT). The outcome measure used in the analysis was the frequency of psychiatric or cardiovascular hospitalisations, emergency room visits, and cardiac catheterisation and revascularisation procedures. These were obtained from serious adverse events reports that were collected for all patients hospitalised during the study period. At study entry, the patients in the two groups were comparable in all clinical and demographic characteristics.
Effectiveness results
The number of psychiatric or cardiovascular hospitalisations was lower in the sertraline group than in the placebo group (55 versus 76). This difference did not achieve statistical significance, (p=0.054).
The majority of the hospitalisations were for cardiovascular events or procedures.
The number of emergency room visits was 26 in the sertraline group and 40 in the placebo group.
The total number of cardiac catheterisation and revascularisation procedures was 41 in the sertraline group and 48 in the placebo group.
Clinical conclusions
The effectiveness study showed that fewer adverse events were observed in the sertraline group than in the placebo group, although the difference was not statistically significant.
Modelling
The authors stated that a decision tree was constructed to describe treatment patterns on the basis of trial data, but no other details of the model were provided.
Measure of benefits used in the economic analysis
No summary benefit measure was used in the economic analysis. In effect, a cost-minimisation analysis was carried out since no statistically significant differences between the groups were found.
Direct costs
The analysis was carried out from the perspective of the third-party payer. Only costs strictly related to hospitalisations, emergency room visits, cardiac procedures and drug use were included in the economic analysis. Outpatient services and rehabilitation costs were excluded since they were not routinely included in discharge summaries. The unit costs were not presented, whereas the quantities of resources used were. The resource data came from the sample of patients that were included in the clinical data. The costs were estimated using Medicare fee schedule. The sertraline costs came from average wholesale prices, assuming perfect compliance. Discounting was not relevant since the costs were incurred during a short timeframe. The price year was not explicitly stated, but the costs were estimated in 2001 and 2002.
Statistical analysis of costs
The Wilcoxon non-parametric test was used to test the statistical significance of differences in costs between the groups.
Indirect Costs
No indirect costs were reported.
Currency

US dollars ($).
Sensitivity analysis
Sensitivity analyses were not carried out.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
Excluding medication costs, the mean cost per patient was $2,733 (+/-6,764) in the sertraline group and $3,326 (+/-7,195) in the control group, (p=0.32).
After including the cost of sertraline, the costs in the sertraline group increased to $3,093.
Synthesis of costs and benefits
A synthesis of the costs and benefits was not relevant since it appears that a cost-minimisation analysis has been carried out.
Authors' conclusions
The use of 24-week sertraline for the treatment of depression in a population with acute coronary syndromes led to a trend towards fewer cardiac or depressive events, without increasing the costs from the perspective of a third-party payer.
CRD COMMENTARY -Selection of comparators
The selection of the comparator was appropriate because no intervention was likely to represent usual care in the authors' setting and it was the basic comparator in the primary clinical trial. You should decide whether this is a valid comparator in your own setting.
Validity of estimate of measure of effectiveness
The evidence came from a clinical trial, which was appropriate for the study question and limited the impact of confounding factors and selection bias. Since the study had been published before, only key characteristics of the patient sample and study design were reported in the current publication. Thus, it was difficult to assess the validity of the study. However, some details of the study, such as the randomised design, the blindness of the study investigators and the baseline comparability of the study groups, ensure the robustness of the clinical information used in the analysis. The evidence came from several centres, thus the study sample appears to have been representative of the patient population. The authors stated that the study was powered to detect statistically significant differences in clinical outcomes (i.e. depressive symptoms), which were not used in this study. In fact, the main outcome measure, the number
